Review decision - July 2011

TA142 is currently under review. Further information about this review can be found on the Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142) [ID541] appraisals in development page.

Review of NICE Technology Appraisal Guidance no. 142; Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancer-treatment induced anaemia

The Institute was proposing that a review of the guidance should be planned into NICE’s work programme. The appraisal would be scheduled to coordinate with the availability of results from the EVALUATE study. Three new erythropoietin-analogue products (including two ‘biosimilar’ products) would be included in the appraisal (subject to formal referral from the Department of Health).

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. 

After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided that a review of the original guidance should be planned into the NICE work programme.

July 2011

This page was last updated: 13 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.